- Home
- SLGL
as 05-14-2025 4:00pm EST
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications.
| Founded: | 1997 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 21.6M | IPO Year: | 2018 |
| Target Price: | $50.00 | AVG Volume (30 days): | 69.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.34 - $16.50 | Next Earning Date: | 05-27-2025 |
| Revenue: | $11,538,000 | Revenue Growth: | 642.47% |
| Revenue Growth (this year): | -31.93% | Revenue Growth (next year): | 31.17% |
Latest Sol-Gel Technologies Ltd. News
SLGL Breaking Stock News: Dive into SLGL Ticker-Specific Updates for Smart Investing
Simply Wall St.
13 days ago
Insider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of Shares
Simply Wall St.
13 days ago
This Sol-Gel Technologies Insider Increased Their Holding In The Last Year
GlobeNewswire
14 days ago
Sol-Gel Announces Reverse Share Split
GlobeNewswire
a month ago
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Zacks
3 months ago
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Simply Wall St.
3 months ago
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?
MT Newswires
5 months ago
Top Premarket Decliners
Zacks
6 months ago
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
Compare SLGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLGL Sol-Gel Technologies Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.